

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY'S DOCKET NUMBER 46342/56603
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>10/009158</b>
INTERNATIONAL APPLICATION NO. <b>PCT/JP00/02763</b>	INTERNATIONAL FILING DATE <b>27 April 2000</b>	PRIORITY DATE CLAIMED <b>27 April 1999</b>		
TITLE OF INVENTION <b>HUMAN CELL LINE SHOWING STABLE EXPRESSION OF CYTOCHROMES P450</b>				
APPLICANT(S) FOR DO/EO/US <b>Masayoshi NANBA, Satoru ASAHI, Sumie YOSHITOMI, and Keiko IKEMOTO</b>				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))        a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).        b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.        c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).        a. <input checked="" type="checkbox"/> is attached hereto.        b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))        a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> have been communicated by the International Bureau.        c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.        d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p> <p>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</p> <p>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</p>				
Items 13 to 20 below concern document(s) or information included:				
<p>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>15. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment.</p> <p>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>17. <input type="checkbox"/> A substitute specification.</p> <p>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</p> <p>23. <input checked="" type="checkbox"/> Other items or information: <b>English Translation of Priority Document – Postcard Check for \$1,014.00 PCT/RO/101      PCT/RO/105      PCT/IB/301 PCT/IB/304      PCT/IPEA/401      PCT/IPEA/402 PCT/IPEA/408      PCT/IS/220      PCT/IPEA/416 PCT/IB/332      PCT/IB/308      Prior Art (7)</b></p>				
<small>IIDS PTO-1449 (1) sheet Information Disclosure Statement (4) pages; English Translation of Patent Application Figures (7) Sheets, Figs, 1, 2, 3, 4, 5, 6, 7 Chart of Enzyme Activity (1) sheet</small>				

U.S. APPLICATION NO. (IF KNOWN) SEE CFR 10/00915	INTERNATIONAL APPLICATION NO. PCT/JP00/02763	ATTORNEY'S DOCKET NUMBER 46342/56603
---	---	---

24. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....	\$1040.00
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....	\$890.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....	\$740.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....	\$710.00
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....	\$100.00

**CALCULATIONS PTO USE ONLY**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$890.00**

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

20     30

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	14 - 20 =	0	x \$18.00	<b>\$0.00</b>
Independent claims	4 - 3 =	1	x \$84.00	<b>\$84.00</b>
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$974.00</b>
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$0.00</b>
<b>SUBTOTAL =</b>				<b>\$974.00</b>
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).				<input type="checkbox"/> 20 <input type="checkbox"/> 30 + <b>\$0.00</b>
<b>TOTAL NATIONAL FEE =</b>				<b>\$974.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input checked="" type="checkbox"/> <b>\$40.00</b>
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,014.00</b>
				<b>Amount to be: refunded</b> <b>\$</b>
				<b>charged</b> <b>\$</b>

- a.  A check in the amount of \$1,014.00 to cover the above fees is enclosed.
- b.  Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1105 A duplicate copy of this sheet is enclosed.
- d.  Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David G. Conlin, Esq. (Reg. 27,026)  
 Dike, Bronstein, Roberts & Cushman  
 Intellectual Property Practice Group of  
 EDWARDS & ANGELL, LLP.  
 P.O. Box 9169  
 Boston, Massachusetts 02209  
 Telephone: (617) 439-4444  
 Facsimile: (617) 439-4170

*Kathryn A. Piffat, Ph.D.*  
 SIGNATURE

**Kathryn A. Piffat, Ph.D.**

NAME

**34,901**

REGISTRATION NUMBER

**October 25, 2001**

DATE

**TRANSMITTAL LETTER TO THE  
UNITED STATES RECEIVING OFFICE**  
Designated/Elected

Date	October 25, 2001
International Application No.	PCT/JP00/02763
Attorney Docket No.	46342-56603

**I. Certification under 37 CFR 1.10 (if applicable)**

EL 789783606 US
Express Mail mailing number

10/009158  
JC18 Rec'd PCT/PTO 25 OCT 2001  
OCTOBER 25, 2001  
Date of Deposit

I hereby certify that the application/correspondence attached hereto is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of person mailing correspondence

JUDITH A. HERRICK
Typed or printed name of person mailing correspondence

**II.  New International Application**

TITLE	HUMAN CELL LINE SHOWING STABLE EXPRESSION OF CYTOCHROMES P450
-------	---

Earliest priority date (Day/Month/Year)
April 27, 1999

**SCREENING DISCLOSURE INFORMATION:** In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (Note: check as many boxes as apply):

- A.  The invention disclosed was **not** made in the United States.
- B.  There is no prior U.S. application relating to this invention.
- C.  The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (*NOTE: priority to these applications may or may not be claimed on form PCT/RO/101 (Request) and this listing does not constitute a claim for priority.*)

application no.		filed on	
application no.		filed on	

D.  The present international application  is identical  contains less subject matter than that found in the prior U.S. application(s) identified in paragraph C.

E.  The present international application  contains additional subject matter not found in the prior U.S. application(s) identified in paragraph C. above. The additional subject matter is found on pages \_\_\_\_\_ and  **DOES NOT ALTER**  **MIGHT BE CONSIDERED TO ALTER** the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37 CFR 5.1. See 37 CFR 5.15

**III.  A Response to an Invitation from the RO/US. The following document(s) is (are) enclosed:**

- A.  A Request for An Extension of Time to File a Response
- B.  A Power of Attorney (General or Regular)
- C.  Replacement pages:

pages	of the request (PCT/RO/101)	pages	of the figures
pages	of the description	pages	of the abstract
pages	of the claims		

- D.  Submission of Priority Documents

Priority document	Priority document
-------------------	-------------------

- E.  Fees as specified on attached Fee Calculation sheet form PCT/RO/101 annex

**IV.  A Request for Rectification under PCT 91       A Petition       A Sequence Listing Diskette**

**V.  Other (please specify):**

The person signing this form is the:	<input type="checkbox"/> Applicant	KATHRYN A. PIFFAT, Ph.D.
	<input checked="" type="checkbox"/> Attorney/Agent (Reg. No.) 34,901	Typed name of signer
	<input type="checkbox"/> Common Representative	Signature